Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Lung Cancer Patients Clinical Trial

Official title:

Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT01257308
• Other study ID #: 99047
• Status: Enrolling by invitation
• Phase: N/A
• First received: December 8, 2010
• Last updated: December 8, 2010
• Start date: August 2010
• Est. completion date: August 2013

Study information

• Verified date: December 2010
• Source: Taipei Medical University WanFang Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• 20 or more than 20 years of age

• The pathological diagnosis confirmed lung cancer

• Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens

• The patient had signed inform consent

Exclusion Criteria:

• pleural effusion or tumor tissue can not be obtained

• the patient is not suitable to join the research according to the judgement by the investigator

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Lung Cancer Patients
• Lung Neoplasms
• Pleural Effusion

Locations

Country	Name	City	State
Taiwan	Taipei Medical University - WanFang Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan,